Tuesday, 07 May 2024
Concert Pharmaceuticals Inc.
13:00 | 5/2/18
Dispatch Tribunal
Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by ($0.16 ...
more»
No Risk Alert Here: Before we dive into any analysis we simply note that Concert Pharmaceuticals Inc (NASDAQ:CNCE) risk is neither elevated nor depressed.
more»
02:18 | 12/1/18
Concord Register
Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE) has an ERP5 rank of 6624. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.
more»
12:15 | 11/1/18
The Ledger Gazette
Zacks Investment Research raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Tuesday, September 26th.
more»
16:00 | 1/1/18
The Ledger Gazette
Concert Pharmaceuticals logo Prudential Financial Inc. decreased its stake in shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 34.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.
more»
00:48 | 25/9/17
The Ledger Gazette
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, September 15th.
more»
08:15 | 23/9/17
Lenox Ledger
Concert Pharmaceuticals Inc (CNCE) market momentum is building as the Awesome Oscillator (AO) is showing a down-trend in the name over the past 5 bars.
more»
12:56 | 17/9/17
The Ledger Gazette
Concert Pharmaceuticals logo Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has received a consensus recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports.
more»
07:30 | 17/9/17
The Ledger Gazette
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday, September 1st.
more»
16:30 | 14/9/17
Dispatch Tribunal
Concert Pharmaceuticals logo Alps Advisors Inc. raised its stake in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 6.3% during the second quarter, according to the company in its most recent 13F filing with the SEC.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |